Premium
SERUM LEVELS OF ETRETINATE (RO 10‐9359) AND ITS METABOLITE (RO 10‐1670)
Author(s) -
Ishizaki Hiroshi,
Masuda Hiroshi,
Kaseda Hidenori,
Kaminaga Tokio,
Hirone Takae
Publication year - 1983
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/j.1346-8138.1983.tb01160.x
Subject(s) - etretinate , metabolite , serum concentration , medicine , side effect (computer science) , endocrinology , chemistry , dermatology , psoriasis , programming language , computer science
Serum levels of Etretinate (ET, Ro 10‐9359) and its metabolite (AM, Ro 10‐1670) were monitored during and after cessation of ET treatment in 12 patients with acquired disorders of keratinization who underwent the ET therapy at initial doses of 30 to 60 mg/day. Studies were made of the possible correlations between ET and AM serum levels, the appearance and disappearance of side effects, and elimination time profiles. Side effects appeared 1 to 2 weeks after the initiation of ET administration in all cases, although serum ET and AM levels at this time varied considerably, indicating individual differences in ET and AM susceptibility in the appearance of side effects. Serum ET and AM levels at the time of disappearance of side effects were lower than those at the time of appearance, suggesting some correlation of side effects with serum levels of ET, AM, or both. Serum level curves for ET and AM after cessation of ET administration were diverse. The maximum ET and AM elimination times from serum were 3 and 6 months, respectively.